» Articles » PMID: 38570586

SOX11/PRDX2 Axis Modulates Redox Homeostasis and Chemoresistance in Aggressive Mantle Cell Lymphoma

Overview
Journal Sci Rep
Specialty Science
Date 2024 Apr 3
PMID 38570586
Authors
Affiliations
Soon will be listed here.
Abstract

Mantle cell lymphoma (MCL) is an incurable B-cell neoplasm characterized by an aggressive behavior, short responses to conventional therapies and SOX11 overexpression, which is associated with aggressive disease features and inferior clinical outcome of patients. Oxidative stress is known to induce tumorigenesis and tumor progression, whereas high expression levels of antioxidant genes have been associated with chemoresistance in different cancers. However, the role of oxidative stress in MCL pathogenesis and the involvement of SOX11 regulating redox homeostasis in MCL cells are largely unknown. Here, by integrating gene set enrichment analysis of two independent series of MCL, we observed that SOX11+ MCL had higher reactive oxygen species (ROS) levels compared to SOX11- MCL primary tumors and increased expression of Peredoxine2 (PRDX2), which upregulation significantly correlated with SOX11 overexpression, higher ROS production and worse overall survival of patients. SOX11 knockout (SOX11KO) significantly reduced PRDX2 expression, and SOX11KO and PRDX2 knockdown (PRDX2KD) had increased ROS levels and ROS-mediated tumor cell death upon treatment with drugs, compared to control MCL cell lines. Our results suggest an aberrant redox homeostasis associated with chemoresistance in aggressive MCL through SOX11-mediated PRDX2 upregulation, highlighting PRDX2 as promising target for new therapeutic strategies to overcome chemoresistance in aggressive MCLs.

References
1.
Beekman R, Amador V, Campo E . SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018; 25(4):299-306. DOI: 10.1097/MOH.0000000000000434. View

2.
Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A . Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012; 72(20):5307-16. PMC: 3763938. DOI: 10.1158/0008-5472.CAN-12-1615. View

3.
Vose J . Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012; 87(6):604-9. DOI: 10.1002/ajh.23176. View

4.
Vegliante M, Palomero J, Perez-Galan P, Roue G, Castellano G, Navarro A . SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013; 121(12):2175-85. DOI: 10.1182/blood-2012-06-438937. View

5.
Palomero J, Vegliante M, Rodriguez M, Eguileor A, Castellano G, Planas-Rigol E . SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014; 124(14):2235-47. DOI: 10.1182/blood-2014-04-569566. View